登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C12H18N4O3
化学文摘社编号:
分子量:
266.30
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
8-Methoxymethyl-3-isobutyl-1-methylxanthine, A cell-permeable selective inhibitor of Ca2+-calmodulin-dependent phosphodiesterase (PDE I; IC50 = 4 µM).
SMILES string
[nH]1c2c(nc1COC)N(C(=O)N(C2=O)C)CC(C)C
InChI
1S/C12H18N4O3/c1-7(2)5-16-10-9(11(17)15(3)12(16)18)13-8(14-10)6-19-4/h7H,5-6H2,1-4H3,(H,13,14)
InChI key
NBLBCGUCPBXKOV-UHFFFAOYSA-N
assay
≥98% (TLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
ethanol: 2 mg/mL
DMSO: 5 mg/mL
shipped in
ambient
storage temp.
10-30°C
Quality Level
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PDE 1
PDE 1
Product does not compete with ATP.
Reversible: no
Target IC50: 4 µM against Ca2+-calmodulin-dependent phosphodiesterase (PDE I)
Disclaimer
Toxicity: Standard Handling (A)
General description
A cell-permeable selective inhibitor of Ca2+-calmodulin-dependent phosphodiesterase (PDE I; IC50 = 4 µM).
A cell-permeable, selective inhibitor of Ca2+-calmodulin-dependent phosphodiesterase (PDE I, IC50 = 4 µM).
Other Notes
Jackson, E.K., et al. 1997. J. Cardiovasc. Pharmacol. 30, 798.
Ahn, H.S., et al. 1989. Biochem. Pharmacol.38, 3331.
Han, P., et al. 1989. J. Biol. Chem.274, 22337.
Ahn, H.S., et al. 1989. Biochem. Pharmacol.38, 3331.
Han, P., et al. 1989. J. Biol. Chem.274, 22337.
Preparation Note
Following reconstitution aliquot and freeze at -20°C. Stock solutions are stable for up to 3 months at -20°C.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
H S Ahn et al.
Biochemical pharmacology, 38(19), 3331-3339 (1989-10-01)
In this study three forms of cyclic nucleotide phosphodiesterase (PDE) isolated from rabbit aorta were pharmacologically characterized, and the consequence of selective inhibition of calmodulin-stimulated PDE (CaM-PDE) and cGMP specific PDE (cG-PDE) was evaluated using PDE inhibitors. The cG-PDE (F1)
E K Jackson et al.
Journal of cardiovascular pharmacology, 30(6), 798-801 (1998-01-22)
The objective this investigation was to determine the relative importance of type I, III, and IV phosphodiesterases in the regulation of cyclic adenosine monophosphate (cAMP) in the renal circulation. In the first experimental series, four groups of isolated rat kidneys
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持